

# SPARK EUROPE WEBINAR SERIES 2024

Wednesdays  
at 4 pm CET

SPARK Europe  
Education

## What is drug repurposing and why is it relevant?

Hans Platteeuw

6 March 2024 | 4 – 5 pm (CET) | Online Webinar



Hans Platteeuw will first give a general introduction into drug repurposing and talk about the pros and cons compared to developing a new chemical entity as drug. Further, based on two use-cases, we will learn about opportunities but also challenges for repurposing and possible solutions.

Hans is a chemist by training. He has a **long-standing experience in product development** in both the innovator, generics and value-added medicines industry. He is a **founder and Chief Scientific Officer of Galenicap**, a company fully dedicated to the development of New Therapeutic Entities. Galenicap acts as an incubator that starts from an academic concept to address a clinical need via existing medications, then transforms the concept into a unique pharmaceutical product with clinical proven endpoints of efficacy and safety and that verifies that all requirements are fulfilled to make the product ready to be available for patients globally including regulatory, intellectual property and financial considerations.

### Online via MS Teams | [Please register here!](#)

Registration to the webinar is required in advance. Please register no later than **5 March 2024**. Please note that you will receive the MS-Teams link and access code the evening before the lecture and that access to last minute registrations, cannot be guaranteed.

[spark-bih.de](http://spark-bih.de) *SPARK is an initiative created at Stanford University, to overcome*  
[bihealth.org](http://bihealth.org) *challenges associated with translation of academic discoveries.*

In unforeseen cases, the organizers may change and update topics and speakers.

SPARK  
FINLAND

SPARK  
TELAVIV

SPARK  
FACULTY OF MEDICINE, HEBRAEA UNIVERSITY

SPARK  
POLAND

SPARK  
NORWAY

SPARKFLI

SPARK  
ZÜRICH

SPARK  
DENMARK

SPARK  
BIH

CHARITÉ **IBIH**  
Innovation  
Der Technologietransfer von Charité und BIH